Literature DB >> 20542643

Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy.

Yi-Ting Huang1, Chun-Chieh Wang, Chien-Sheng Tsai, Chyong-Huey Lai, Ting-Chang Chang, Hung-Hsueh Chou, Swei Hsueh, Chien-Kuang Chen, Steve P Lee, Ji-Hong Hong.   

Abstract

PURPOSE: To study the outcomes of patients with adenocarcinoma/adenosquamous carcinoma (AC/ASC) of the cervix primarily treated with radiotherapy (RT), identify the prognostic factors, and evaluate the efficacy of concurrent chemoradiotherapy (CCRT) or salvage surgery. METHODS AND MATERIALS: A total of 148 patients with Stage I-IVA AC/ASC of cervix after full-course definitive RT were included. Of the 148 patients, 77% had advanced stage disease. Treatment failure was categorized as either distant or local failure. Local failure was further separated into persistent tumor or local relapse after complete remission. The effectiveness of CCRT with cisplatin and/or paclitaxel was examined, and the surgical salvage rate for local failure was reviewed.
RESULTS: The 5-year relapse-free survival rate was 68%, 38%, 49%, 30%, and 0% for those with Stage IB/IIA nonbulky, IB/IIA bulky, IIB, III, and IVA disease, respectively, and appeared inferior to that of those with squamous cell carcinoma of the cervix treated using the same RT protocol. Incomplete tumor regression after RT, a low hemoglobin level, and positive lymph node metastasis were independent poor prognostic factors for relapse-free survival. CCRT with weekly cisplatinum did not improve the outcome for our AC/ASC patients. Salvage surgery rescued 30% of patients with persistent disease.
CONCLUSION: Patients with AC/ASC of the cervix primarily treated with RT had inferior outcomes compared to those with squamous cell carcinoma. Incomplete tumor regression after RT was the most important prognostic factor for local failure. Salvage surgery for patients with persistent tumor should be encouraged for selected patients. Our results did not demonstrate a benefit of CCRT with cisplatin for this disease.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20542643     DOI: 10.1016/j.ijrobp.2010.02.009

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  29 in total

1.  Combination of external beam radiotherapy and Californium (Cf)-252 neutron intracavity brachytherapy is more effective in control of cervical squamous cell carcinoma than that of cervical adenocarcinoma.

Authors:  Yanli Xiong; Jia Liu; Shu Chen; Qian Zhou; Wenjing Xu; Chen Tang; Yonghong Chen; Mei Yang; Xin Lei
Journal:  Med Oncol       Date:  2015-08-14       Impact factor: 3.064

2.  Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation.

Authors:  Peter G Rose; James J Java; Charles W Whitney; Frederick B Stehman; Rachelle Lanciano; Gillian M Thomas
Journal:  Gynecol Oncol       Date:  2014-08-23       Impact factor: 5.482

3.  Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix.

Authors:  Muneaki Shimada; Shoji Nagao; Keiichi Fujiwara; Nobuhiro Takeshima; Ken Takizawa; Tadahiro Shoji; Toru Sugiyama; Satoshi Yamaguchi; Ryuichiro Nishimura; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2016-07-05       Impact factor: 3.402

4.  Integrating imaging and RNA-seq improves outcome prediction in cervical cancer.

Authors:  Jin Zhang; Ramachandran Rashmi; Matthew Inkman; Kay Jayachandran; Fiona Ruiz; Michael R Waters; Perry W Grigsby; Stephanie Markovina; Julie K Schwarz
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

5.  Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis.

Authors:  Juan Zhou; San-Gang Wu; Jia-Yuan Sun; Feng-Yan Li; Huan-Xin Lin; Qiong-Hua Chen; Zhen-Yu He
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-19       Impact factor: 4.553

6.  Type C2 radical hysterectomy may improve outcomes of locally advanced mucinous adenocarcinoma of the uterine cervix.

Authors:  Shinichi Okame; Atsumi Kojima; Norihiro Teramoto; Yuko Shiroyama; Takashi Yokoyama; Kazuhiro Takehara; Takayoshi Nogawa
Journal:  Int J Clin Oncol       Date:  2015-12-22       Impact factor: 3.402

7.  Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.

Authors:  Yan Xiao; Ying-Kun Ren; Hui-Jun Cheng; Li Wang; Su-Xia Luo
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 8.  Adenocarcinoma of the uterine cervix: why is it different?

Authors:  Keiichi Fujiwara; Bradley Monk; Mojgan Devouassoux-Shisheboran
Journal:  Curr Oncol Rep       Date:  2014-12       Impact factor: 5.075

9.  Post-radiotherapy hysterectomy does not benefit females with cervical adenocarcinoma.

Authors:  Elen Cristiane Augusto Souza; Daniel Zaidan Santos; Jose Carlos Campos Torres; Diama Bhadra Vale; Joana Froes Bragança; Julio Cesar Teixeira
Journal:  Mol Clin Oncol       Date:  2020-10-26

10.  Long-term Outcomes of Cervical Adenocarcinoma Treated With Concurrent Chemoradiotherapy Using Paclitaxel and Cisplatin.

Authors:  Yoshihisa Arakaki; Takuro Ariga; Joichi Heianna; Yuko Shimoji; Tadaharu Nakasone; Yusuke Taira; Tomoko Nakamoto; Takuma Ooyama; Wataru Kudaka; Itomi Kaneshima; Kumiko Nishihira; Keiko Mekaru; Yoichi Aoki
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.